Log in

NASDAQ:INTI - Inhibitor Therapeutics Stock Price, Forecast & News

-0.03 (-41.10 %)
(As of 03/27/2020 04:00 PM ET)
Today's Range
Now: $0.04
50-Day Range
MA: $0.07
52-Week Range
Now: $0.04
Volume685 shs
Average Volume51,870 shs
Market Capitalization$15.93 million
P/E RatioN/A
Dividend YieldN/A
Inhibitor Therapeutics Inc. operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.
Read More

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:INTI



Sales & Book Value

Annual SalesN/A



Market Cap$15.93 million
Next Earnings Date4/2/2020 (Estimated)
OptionableNot Optionable

Receive INTI News and Ratings via Email

Sign-up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter.

Inhibitor Therapeutics (NASDAQ:INTI) Frequently Asked Questions

How has Inhibitor Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Inhibitor Therapeutics' stock was trading at $0.0756 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INTI shares have decreased by 43.1% and is now trading at $0.0430. View which stocks have been mosted impacted by Coronavirus.

When is Inhibitor Therapeutics' next earnings date?

Inhibitor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Inhibitor Therapeutics.

Has Inhibitor Therapeutics been receiving favorable news coverage?

News stories about INTI stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inhibitor Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutInhibitor Therapeutics.

Who are some of Inhibitor Therapeutics' key competitors?

Who are Inhibitor Therapeutics' key executives?

Inhibitor Therapeutics' management team includes the following people:
  • Mr. Nicholas Jon Virca, Pres & CEO (Age 73)
  • Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50)

What is Inhibitor Therapeutics' stock symbol?

Inhibitor Therapeutics trades on the NASDAQ under the ticker symbol "INTI."

How do I buy shares of Inhibitor Therapeutics?

Shares of INTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inhibitor Therapeutics' stock price today?

One share of INTI stock can currently be purchased for approximately $0.04.

How big of a company is Inhibitor Therapeutics?

Inhibitor Therapeutics has a market capitalization of $15.93 million. Inhibitor Therapeutics employs 2 workers across the globe. View additional information about Inhibitor Therapeutics.

What is Inhibitor Therapeutics' official website?

The official website for Inhibitor Therapeutics is http://www.inhibitortx.com/.

How can I contact Inhibitor Therapeutics?

The company can be reached via phone at 813-864-2559.

MarketBeat Community Rating for Inhibitor Therapeutics (NASDAQ INTI)

Community Ranking:  1.4 out of 5 (star)
Outperform Votes:  3 (Vote Outperform)
Underperform Votes:  8 (Vote Underperform)
Total Votes:  11
MarketBeat's community ratings are surveys of what our community members think about Inhibitor Therapeutics and other stocks. Vote "Outperform" if you believe INTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/28/2020 by MarketBeat.com Staff

Featured Article: Current Ratio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel